Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Prime Medicine (PRME) Announces Proposed $125M Share Offering
-
Prime Medicine Announces Proposed Public Offering of Common Stock
-
Adagio Medical to Go Public via Merger with ARYA Sciences Acquisition Corp IV (ARYD)
-
Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation Technologies
-
Metagenomi (MGX) Closes $93.75M IPO
-
Metagenomi Announces Closing of Initial Public Offering
-
Presto (PRST) Raises $6M, Wins Final Appeal Against XAC
-
Presto Automation Raises $6.0 Million and Wins Final Appeal in Case Against XAC
-
AtlasClear Announces Closing of Business Combination with Quantum FinTech Acquisition Corporation and Acquisition of Wilson-Davis & Co.
-
Chardan Downgrades Synlogic Inc. (SYBX) to Neutral 'on Early Termination of Synpheny-3 Trial'
-
Metagenomi (MGX) Prices 6.25M Share IPO at $15/sh
-
Sensorion Announces a €50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors
-
Metagenomi Announces Pricing of Initial Public Offering
-
4D Molecular Therapeutics (FDMT) PT Raised to $38 at Chardan, 'Phase II wAMD Data Set Up a Competitive GT Profile'
-
Silence Therapeutics (SLN) Prices 5.71M Share Offering at $21/sh
-
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
-
Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series
-
Cohen & Company Capital Markets Highlights Strong 2023
-
Collective Audience (CAUD) Announces 3.22M Share and Warrant Offering by Selling Stockholders
-
Metagenomi (MGX) Announces Proposed IPO
-
Bayview Acquisition Corp Announces the Separate Trading of its Ordinary Shares and Rights Commencing December 28, 2023
-
BWG Strategy Appoints Industry Veteran to Lead Healthcare Research
-
Bayview Acquisition Corp Announces Closing of Upsized $60 Million Initial Public Offering
-
Bruush Oral Care (BRSH) and Arrive Technology Announce Agreement and Plan of Merger
-
Bruush Oral Care Inc. and Arrive Technology Inc. Announce Agreement and Plan of Merger
-
Bayview Acquisition Corp (BAYAU) Prices 6M Unit IPO at $10/unit
-
Bayview Acquisition Corp Announces Pricing of Upsized $60 Million Initial Public Offering
-
Coya Therapeutics Announces Closing of $26.5 Million Private Placement
-
Coya Therapeutics (COYA) Announces $26.5 Million Private Placement
-
Coya Therapeutics Announces $26.5 Million Private Placement
-
NOVONIX Announces Participation in December Investor Events
-
Global Lights Acquisition Corp Announces the Separate Trading of Its Ordinary Shares and Rights, Commencing on December 4, 2023
-
Chardan Capital Markets Starts Lexeo Therapeutics (LXEO) at Buy
-
Gardiner Healthcare Acquisitions Corp. Announces Intent to Extend
-
Chardan Capital Markets Starts Notable Labs, Inc. (NTBL) at Buy on the 'potential of its proprietary Predictive Precision Medicine Platform'
-
Presto Raises Capital from Remus Investor Group, Announces Addition of Two Board Members, and Significant Cost Reductions
-
Global Lights Acquisition Corp Announces Closing of $69 Million Initial Public Offering
-
VIVOPOWER ANNOUNCES “SUM OF THE PARTS” STRATEGIC VALUE MAXIMISATION REVIEW
-
Global Lights Acquisition Corp (GLACU) Announces Pricing of $60 Million Initial Public Offering
-
Global Lights Acquisition Corp Announces Pricing of $60 Million Initial Public Offering
-
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
-
Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million¹
-
Chardan Capital Markets Upgrades ProQR Therapeutics N.V. (PRQR) to Buy
-
ProQR Announces Third Quarter 2023 Operating and Financial Results
-
Lexeo Therapeutics Announces Pricing of Initial Public Offering
-
Abri SPAC I, Inc. Announces Completion of Business Combination
-
Sonnet BioTherapeutics (SONN) Announces Pricing of $4.55 Million Underwritten Public Offering
-
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
-
Gardiner Healthcare Acquisitions Corp. Announces Intent to Extend
-
Notable Labs Closes Merger Transaction With VBL Therapeutics

